Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRG50635 multiple ascending dose study in sporadic and familial amyotrophic lateral sclerosis
NL-OMON58699Phase 1Completed
- Sponsor
- Verge Genomics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VRG50635 in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Verge Genomics. Started Mar 2024; status: completed.
02
Drugs
VRG50635
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON58699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58699.